News | Venous Therapies | September 11, 2017

Veniti Announces Boston Scientific Distribution Agreement for Vici Venous Stent

Stent designed for venous disorders to be sold under limited global distribution agreement; device still investigational in the U.S.

Veniti Announces Boston Scientific Distribution Agreement for Vici Venous Stent

September 11, 2017 — Veniti Inc. announced that Boston Scientific will distribute the Vici Venous Stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed.

Launched in 2014, the Vici Venous Stent has gained wide market acceptance for its balance of end-to-end strength, flexibility and lumen quality to address the challenging requirements of venous disorders. It is available in a conventional delivery system, as well as the novel Vici Verto Venous Stent System, providing more control in the landing of stents in areas of critical blood flow.

Veniti is currently conducting the VIRTUS Trial to evaluate the safety and efficacy of the Vici Venous Stent for the treatment of chronic iliofemoral venous outflow obstruction under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption.

For more information: www.veniti.com

Related Content

Videos | Stents Bifurcation| November 15, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Videos | Business| November 09, 2017
A discussion with Peter L.
SCAI Successful in Securing Inpatient Status for AMI-PCI Patients
News | Business| November 09, 2017
In the Society for Cardiovascular Angiography and Interventions’ (SCAI) comment letter to the Centers for Medicare...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
Videos | Stents Bioresorbable| November 07, 2017
A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyteri
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies| November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Overlay Init